The purchase of the Swiss INRAAIC laboratory forms part of the international expansion strategy of diagnostic company Analiza, for growth in the market of clinical analysis, allergy detection and personalised medicine at an international level.

The INRAAIC (Institut de Recherche Appliquee en Allergologie et Immunologie Clinique) laboratory was originally created from the Allergology and Clinical Immunology Department of the La Tour Hospital in Meyrin, near Geneva, Switzerland. Since 2000, the Allergology and Clinical Immunology Department of the La Tour Hospital is fully integrated in the INRAAIC organisation.

Under the leadership of Dr Pierre Gumoswki, a renowned doctor and specialist in Allergies and Immunology, the INRAAIC laboratory offers its clients a wide range of routine tests in the field of immunology and allergies, as well as clinical advice and specific tests for different rare illnesses caused by immunodeficiency. 

This new incorporation complements and expands the activity of the ADR-AC laboratory, acquired by the diagnostic company in 2019. In this way, Analiza is now present at a national level in the cities of Geneva and Bern, being able to offer service to doctors and patients in French, English, German and Italian.

During the pandemic, the synergies developed between both laboratories have provided new diagnostic tools for the so-called “Long COVID-19” or persistent COVID, among other conditions. The collaboration of both companies has contributed to the creation of a protocol for reactions to the COVID-19 vaccine in the form of diagnosis by skin prick tests, as well as basophil activation tests for different COVID-19 vaccines.

Since its creation, INRAAIC has participated in various institutional and governmental research programmes, as well as in research activities in cooperation with pharmaceutical companies such as Glaxo, MSD and Sallergenes-Pasteur.